Innovative Diagnostics PetDx's flagship product, OncoK9, leverages advanced genomic and next-generation sequencing technology to provide early cancer detection in dogs, positioning the company as a leader in pet health diagnostics.

Recent Funding & Growth With $62 million raised in Series B funding and recent leadership appointments, PetDx is poised to expand its market presence and accelerate adoption of its multi-cancer detection tests across veterinary clinics.

Strategic Partnerships The collaboration with Petco to offer OncoK9 in on-site clinics presents a significant sales opportunity to reach a wider network of pet care providers and increase product adoption.

Market Expansion Potential The company's focus on molecular diagnostics and genomic analysis aligns with growing trends in personalized veterinary medicine, providing opportunities to develop additional tests and services tailored to pet health.

Growth in Veterinary Market As a biotech startup with a dedicated focus on pet health, PetDx can target expanding veterinary clinics and specialty practices seeking innovative solutions for early disease detection, creating multiple avenues for sales growth.